resources
Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment
Publication
Preview - This content has been restricted to logged in users only.
The medical need for better cancer therapies is undiminished, while drug development is slow and costly, mainly due to the large risk of toxicity of novel molecules.
Publication
PEGylated liposomes provided the highest drug biostability amongst all formulations in horse serum. PEGylated DPPC liposomes had t1/2 =77.3 =/- 9.6 min compared to 9.7 =/- 2.3 min for free DS. In vitro cytotoxicity on wild type and resistant colorectal cancer cell lines was evaluated by MTT assay. All liposomal formulations of DS were cytotoxic to both the wild type and resistant colorectal cancer cell lines and were able to reverse chemoresistance at low nanomolar concentrations. In conclusion, PEGylated liposomes have a greater potential to be used as an anticancer carrier for disulfiram.